£10.8M
Eli Lilly and Company backed the round to support the development of the company's internal pipeline.
MiNA Therapeutics
MiNA Therapeutics develops small activating RNA medicines to restore normal cell function.
£33.8MTotal raised
MiNA Therapeutics is a biotechnology company pioneering small activating RNA therapeutics to restore or boost normal cell functions. The firm focuses initially on developing treatments for cancer and genetic diseases.
Categories
Team
RH
Robert Habib
CEO
Robert is the chief executive of MiNA Therapeutics. He previously worked in mergers and acquisitions at Deutsche Bank.
LinkedIn
Robin Wright
CFO
Robin brings extensive financial leadership experience across life sciences, serving as chief financial officer at MiNA Therapeutics and Pharming Group, alongside a chairmanship at Barinthus Biotherapeutics.
LinkedInInvestors
- £10.8M
- £23.0MaMoonLead
Funding history
£23.0M
The financing round was led by aMoon and will support clinical trials and research pipelines.